CHERNOVSKAYA, TATYANA VENIAMINOVNA,DENISOV, LEV ALEXANDROVICH,RUDENKO, ELENA GEORGIEVNA,KLENOVA, ANGELINA VSEVOLODOVNA,MOROZOV, DMITRIY
申请号：
ECSP13012398
公开号：
ECSP13012398A
申请日:
2013.01.18
申请国别(地区):
EC
年份:
2013
代理人:
摘要：
The invention relates to the pharmaceutical and medical industries, in particular to the novel PEG-interferon derivatives and to the discovery of a novel, highly stable, functional conjugate of interferon to polyethylene glycol with interferon alpha activity, with reduced immunogenicity, with biological effects. Prolonged and improved pharmacokinetic parameters of general formula. Where: n- integral values from 227 to 10,000, so the molecular weight of PEG is around 10,000 - 40,000 Da； m - integer? 4； IFN-natural or recombinant polypeptide having IFN-alpha activity. Also,The invention is related to drugs and contains the commonness in formula (1)Ideal aggregations and therapeutically acceptable aggregations containing treatments for viral infections and cancers and diseases associated with primary or secondary immunodeficiency viruses The invention relates to the use of formula compounds (1) in pharmaceutical products having antiviral, anti-corrosion and immunity. 1. Approximation and / or treatment of diseases related to the combination of primary or quadratic equations (1) and containers containing such pharmaceutical ingredients.La invención está relacionada a la industria farmacéutica y medicina, en particular, al nuevo PEG-interferón derivados y al descubrimiento de un conjugado nuevo funcional, altamente estable de interferón a polietileno glicol con una actividad de interferón alfa, con inmunogenicidad reducida, con efectos biológicos prolongados y parámetros fármaco-kinéticos mejorados de fórmula general. Donde:n- valores integrales de 227 a 10 000, así que el peso molecular de PEG es de alrededor de 10 000 - 40 000 Da；m - integer ? 4；IFN - natural o recombinante polipéptido teniendo la actividad de IFN-alfa.También, la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (1), composiciones farmacéuticas conteniendo PEG-IFN conjugado y terapéuticamente aceptable excipientes ideales para el tratamiento de infecciones virales
